Oncology remains a core therapeutic area at AbbVie, featuring a robust portfolio of marketed products and a promising oncology pipeline. AbbVie is currently seeking a dynamic Executive Medial Director/Sr. Scientific Director for Medical Affairs, Precision Medicine, to lead US CDx strategy in oncology. This role requires a strong background in cancer diagnostics, pathology, biomarkers, and cancer therapeutics, as well as a demonstrated commitment to precision medicine.

Key Responsibilities

• Lead and deliver a comprehensive, US focused medical strategy for upcoming CDx launches, overseeing execution of key deliverables.
• Develop and implement the medical affairs strategy for upcoming CDx launches.
• Build and maintain key external relationships with diagnostic partners, academic and community labs, and reference labs.
• Cultivate relationships with expert pathologists and key opinion leaders.
• Forge strong partnerships with leading pathology societies and develop EQA/PT programs.
• Represent Medical Affairs in cross-functional Oncology Precision Medicine teams across the organization.
• Act as the medical affairs lead on the integrated brand team and medical affairs team.
• Develop and execute a biomarker and CDx evidence generation plan in collaboration with precision medicine, HEOR, and TA teams.
• Execute key functional deliverables aligned with the CDx medical strategy, including:
  • Evidence generation to address biomarker and testing gaps.
  • Medical review of scientific publications.
  • Educational initiatives for both internal and external audiences on biomarkers and testing.
  • Review of medical promotional materials for biomarker and testing content.
  • Collaboration with Value and Evidence teams on guideline strategies for biomarkers and testing.
  • Insight generation via advisory boards and engagements with external experts.
  • Develop and implement a congress strategy for pathologists, including EE engagements and digital initiatives.
  • Support oncology congresses with biomarker and testing materials in partnership with the TA team.